Valuation: Insmed Incorporated

Market Cap 26.96B 24.49B 22.63B 20.44B 38.57B 2,531B 39.93B 272B 108B 1,358B 101B 99.01B 4,303B P/E 2026 *
-75x
P/E 2027 * 172x
Enterprise Value 26.44B 24.02B 22.2B 20.05B 37.84B 2,483B 39.17B 267B 106B 1,332B 99.22B 97.13B 4,221B EV / Sales 2026 *
14.2x
EV / Sales 2027 * 8.69x
Free-Float
98.99%
Yield 2026 *
-
Yield 2027 * -
1 day+1.42%
1 week+5.84%
Current month+9.15%
1 month+27.64%
3 months-0.70%
6 months+12.59%
Current year-29.40%
1 week 116.89
Extreme 116.8904
124.92
1 month 92.62
Extreme 92.625
124.92
Current year 90.39
Extreme 90.39
186.19
1 year 90.39
Extreme 90.39
212.75
3 years 21.92
Extreme 21.92
212.75
5 years 16.04
Extreme 16.04
212.75
10 years 11.31
Extreme 11.31
212.75
Manager TitleAgeSince
Chief Executive Officer 57 10/09/2012
Chief Tech/Sci/R&D Officer 62 19/12/2019
Chief Operating Officer 57 14/11/2019
Director TitleAgeSince
Chairman 75 16/06/2009
Chairman 57 08/11/2018
Director/Board Member 72 29/05/2014
Date Insider Type Main position Quantity % Market Cap. Importance
19/10/26 Free

Director

6,139 0.0028%
19/10/26 Free

Director

6,139 0.0028%
09/09/26 Sell

Director

-25,000 0.0114%
Change 5-day change 1-year change 3-year change Capi.($)
+1.42%+5.84%-36.40%+402.78% 26.96B
-1.29%-3.91%+51.98%+69.06% 65.56B
-3.08%-1.57%+7.34%+88.06% 60.41B
-0.91%+0.67%+23.36%+87.44% 55.76B
-1.26%-1.45%+12.43%+117.42% 46.98B
-0.15%-5.06%+20.00%+29.27% 43.63B
+0.23%+2.14%+14.85%+46.22% 36.7B
-3.15%-16.63%+146.30%+685.27% 36.09B
-2.15%-3.32%+75.25%+56.16% 32.9B
-0.94%-6.69%+43.08%-2.01% 24.45B
Average -1.12%-1.92%+35.82%+157.97% 43B
Weighted average by Cap. -1.27%-1.74%+34.89%+141.12%

Financials

2026 *2027 *
Net sales 1.86B 1.69B 1.56B 1.41B 2.66B 175B 2.76B 18.79B 7.44B 93.79B 6.98B 6.84B 297B 2.99B 2.72B 2.51B 2.27B 4.28B 281B 4.43B 30.21B 11.97B 151B 11.23B 10.99B 478B
Net income -357M -325M -300M -271M -511M -33.55B -529M -3.61B -1.43B -18.01B -1.34B -1.31B -57.04B 167M 152M 141M 127M 240M 15.72B 248M 1.69B 670M 8.44B 628M 615M 26.72B
Net Debt -514M -467M -432M -390M -736M -48.31B -762M -5.19B -2.06B -25.92B -1.93B -1.89B -82.11B -949M -862M -797M -720M -1.36B -89.11B -1.41B -9.58B -3.8B -47.82B -3.56B -3.49B -151B
Projected Income Statement - Annual - Insmed Incorporated
Logo Insmed Incorporated
Insmed Incorporated is a global biopharmaceutical company. It is advancing a diverse range of approved and mid- to late-stage investigational medicines and drug discovery. Its advanced programs are in pulmonary and inflammatory conditions, including a therapy approved in the United States, Europe, and Japan to treat a chronic, debilitating lung disease. Its pre-clinical research programs encompass a range of technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Its first commercial product, ARIKAYCE (amikacin liposome inhalation suspension), is used for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. Its pipeline includes clinical-stage programs, brensocatib, TPIP, and INS1201 and pre-clinical research programs. Its INS1148 is an investigational monoclonal antibody.
Employees
1,664
Date Price Change Volume
16/11/26 $122.88 +1.42% 2,233,188
13/11/26 $121.16 +2.62% 1,543,624
12/11/26 $118.07 -2.22% 2,397,944
11/11/26 $120.75 +1.05% 1,488,927
10/11/26 $119.49 +2.92% 3,346,741
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
MarketScreener Ratings - Insmed Incorporated
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
24
Last Close Price
122.88USD
Average target price
194.18USD
Spread / Average Target
+58.03%
  1. Stock Market
  2. Stocks
  3. INSM Stock